Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Crx2.0
Cortexin – Forschung
Überwiegend Mechanismus / Beobachtung
18 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Cortexin sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus mittelwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2016–2026 mit einer typischen Studiengröße von 110 Teilnehmenden.
Basierend auf 18 Studien · 1 Meta-Analyse · 2 RCTs · 938 Teilnehmende insgesamt
Konfidenz
Mittlere Konfidenz
Nach Outcome
Cognitive functionWird für eine schnellere neurologische/kognitive Erholung nach Schlaganfall vermarktet, doch die stützenden Humandaten sind unverblindet und es schneidet häufig schlechter ab als Vergleichsmedikamente. · Nicht belegt
Überwiegend Mechanismus / Beobachtung16 Studien
Neuroprotection & brain agingEin aus dem Gehirn gewonnenes Polypeptid, das auf Neuroprotektion nach Schlaganfall untersucht wird; plausible Effekte auf Rezeptorebene bzw. antioxidative Wirkungen in Tierversuchen, jedoch nicht besser als Kochsalzlösung in einem strengen Tiervergleich, und Humanstudien sind unverblindet. · Nicht belegt
Überwiegend Mechanismus / Beobachtung7 Studien
Aktives Forschungsgebiet
13 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2021
201620212026
1Systematische Übersicht2026
The review underscores the importance of developmental neuroscience frameworks for identifying sex-specific risk markers and informing mechanism-based early interventions.
Ladouceur CD · Annual review of clinical psychology (2026)
In girls, such vulnerability may arise from the effects of gonadal hormones on this circuitry, heightening neural sensitivity to threat and dampening reward responsiveness, thereby biasing socio-affective learning toward avoidance during a period of heightened neuroplasticity.
Integrating evidence from human neuroimaging and animal studies, this review highlights convergent hormonal pathways that shape this circuitry and confer risk for affective disorders.
The review underscores the importance of developmental neuroscience frameworks for identifying sex-specific risk markers and informing mechanism-based early interventions.
Future research should prioritize longitudinal designs, diverse populations, and standardized methodologies to deepen our understanding of the relationship between anxiety, depression, and rosacea.
Sharifi S, Katamanin O, Jafferany M. · Archives of dermatological research (2025)
The complex interaction between rosacea and its psychological outcomes is thought to rely on inflammatory mediators, lipid metabolism, and neurotropic factors.
Certain treatment options, including carvedilol, paroxetine and Cortexin, may target these core processes and hence, help alleviate psychological sequalae.
Bearing these insights in mind, dermatologists should focus on adopting interdisciplinary treatment plans.
Conclusion The results of the study support considering transcranial electrical stimulation as an effective and pathogenetically justified component of complex therapy for post-COVID syndrome with neurological symptoms, accompanied by chronic fatigue and cognitive impairment.
Rubel AD, Gumenyuk LN, Bobrik YV. · Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury (2025)
In both groups, Cortexin was used as the pharmacotherapy.
The effectiveness of the treatment was evaluated using the MFI-20, MoCA, and CGI-S scales, as well as plasma levels of TNF- α , IL-1 β , and IL-6.
Conclusion The results of the study support considering transcranial electrical stimulation as an effective and pathogenetically justified component of complex therapy for post-COVID syndrome with neurological symptoms, accompanied by chronic fatigue and cognitive impairment.
The domestic drug Cortexin is one of the most promising drugs for further clinical trials.
Putilina MV. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2025)
Traditionally applied treatment standards, strict glycemic control does not allow us to talk about complete correction of manifestations and/or reducing the risk of developing DPN without CI or mild CI.
In recent years, the possibilities of peptide drugs to reduce CI and chronic neuropathic pain have been actively studied.
Neuropeptides of animal origin combine the functions of hormones, growth factors, neurotransmitters, ion channel ligands, and anti-inflammatory agents.
Cortexin is presented as a promising drug that meets modern requirements for rational neuroprotection in chronic cerebral ischemia.
Zakharov DV, Zakharova IV. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2025)
The article reviews the key pathogenetic mechanisms of CCI: microcirculatory disorders, glutamate-mediated excitotoxicity, oxidative stress and neuroinflammation.
The results of experimental and clinical studies demonstrating the effectiveness of Cortexin in conditions of ischemic brain damage are presented.
Biomarkers confirming the effect of Cortexin on the reduction of neurotoxicity (in particular, NR2-peptide concentration), enhancement of antioxidant activity and modulation of cytokine profile are analyzed separately.
Conclusion The comprehensive therapy with Cortexin proved to be highly effective, safe, and well-tolerated in patients with neurological complications of T2DM, and it is recommended for use in general clinical practice.
· Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2026)
Of the participants, 70.6% were females and 29.4% were males, aged 45 to 70 years (mean age: 60.8±0.71 years).
Results The regression of cognitive symptoms in group 1 patients was superior to that in group 2 (6.0 times vs. 1.7 times), as confirmed by a 1.2-fold increase in the average MoCA score after 3 months of follow-up ( p <0.001).
In the Cortexin group, the mean HADS anxiety score decreased by 1.6 times, and the mean depression score decreased by 1.7 times, with minimal changes noted in the control group ( p <0.001).
Conclusion The findings suggest that a multimodal approach to restorative treatment, combining neuroprotective medications with high-intensity magnetic therapy, demonstrates considerable therapeutic efficacy in the medical rehabilitation of patients with ischemic stroke.
Results In Group I, a 27% reduction in lower limb spasticity was noted on day 14, whereas Group II exhibited a 25% reduction, with Group III demonstrating a 15% reduction.
USDG data indicated that 52% of patients in Group I showed increases in maximum and linear blood flow velocity in both the right and left vertebral arteries after treatment, compared to 41% in Group II and 20% in Group III.
The mean score on the NIH Stroke Scale for Group I patients at discharge was 9.3±0.2 points, and the Rankin scale score was 2.1±0.2 points.
In this situation, it is important to give preference to the complex administration of drugs with a multimodal mechanism of action, as well as to create optimal combinations of drugs that potentiate each other's effects.
Ivonina NA, Petrov KB. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2025)
The second study of patients showed a significant improvement in vestibular balance, a decrease in anxiety and sleep disorders, especially in patients receiving complex therapy.
In the third test, patients receiving Cortexin and Recognan showed statistically significant positive changes in almost all indicators: VSS-ST-V and VSS-ST-A subscales (average score 27.15±2.83), insomnia, and ASI-3.
Patients receiving complex therapy had the most statistically significant changes.
Both dosage forms have shown a comparable safety profile, are therapeutically equivalent, and can be used in clinical practice at both the hospital and outpatient stages of managing patients with acute cerebral circulatory disorders.
The study included 490 patients with acute IS, male (54.1%) and female (45.9%) aged from 30 to 80 years (average age 63.97+8.5 years), divided into 2 groups: 1 - main (Cortexin intravenous form, n =246), 2 - comparison (Cortexin intramuscular form, n =244).
Results The proportion of patients who reached 0-2 on the mRS scale on day 90 was 93.64% and 86.50% in the groups receiving Cortexin intravenously and intramuscularly, respectively.
According to the MMSE scale, by the day of completion of the study, the overall dynamics of the average score in group 1 was 4.11, in the comparison group 3.88 ( p =0.249).
Conducting two treatment courses with the inclusion of the drug Cortexin leads to a significant reduction in the frequency and severity of manifestations of myotonic and hypertensive-hydrocephalic syndromes in children with both acute and chronic hypoxic-ischemic central nervous system damage.
Degtyareva VG, Drobyshev VA, Poteryaeva EL. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024)
In children of subgroups 1A and 2A, the frequency and severity of symptoms after therapy differed statistically significantly from those in patients of groups 1B and 2B.
Against the background of Cortexin use, 73.4% of the examined subgroups 1A and 71.3% - 1B showed an increase in bioelectric activity in the range of 10-12 Hz, an increase in signal amplitude.
Conducting two treatment courses with the inclusion of the drug Cortexin leads to a significant reduction in the frequency and severity of manifestations of myotonic and hypertensive-hydrocephalic syndromes in children with both acute and chronic hypoxic-ischemic central nervous system damage.
Conclusion Cortexin therapy has been shown to be effective, safe and well tolerated in young people with cognitive deficits in the poststroke period.
Shchepankevich LA, Rerikh KV, Gribacheva IA, Popova TF, Taneeva EV, Tyazhelnikov NE, Sokolova DV, Boznyakov AV. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024)
Low quality of life scores persisted until the third visit; a significant improvement in SF-36 results was recorded at visit 4 and persisted with a positive trend at the fifth visit.
Delayed neuropsychological testing showed encouraging results - the achieved level of cognitive functioning was maintained (28.0±1.1).
According to SF-36 questionnaire at the stage of inclusion in the observation, low results were noted, which indicated the negative impact of the underlying disease on the daily life of the patient who had suffered a stroke.
Similar functional outcome was observed for saline control, Cognistar®, Cerebrolysat® and Cortexin®; in contrast, a significantly improved neurological outcome was observed with Cerebrolysin® treatment.
Zhang L, Chopp M, Wang C, Zhang Y, Lu M, Zhang T, Zhang ZG. · J Neurol Sci (2019)
Independent, prospective, randomized, double-blind, placebo-controlled rodent embolic-stroke comparison of four brain-hydrolysate drugs vs saline
Cortexin produced functional outcomes and lesion volumes NO DIFFERENT from saline
Only cerebrolysin significantly improved neurological outcome vs saline and vs the comparator drugs
The limited number of eligible studies for Actovegin (n = 2 trials,563 participants) and Cortexin, (n = 1 trial,80 participants) precluded meta-analyses but data suggested potential efficacy and no safety concerns.
Alsulaimani RA, Quinn TJ. · Cereb Circ Cogn Behav (2021)
Independent systematic review and meta-analysis of animal-derived nootropics (Cerebrolysin, Actovegin, Cortexin) in cognitive disorders, using Cochrane risk-of-bias and GRADE
For cortexin, only ONE eligible trial (80 participants) was found — too few to meta-analyse, so no pooled cortexin estimate could be generated
Across the drug class, risk of bias was moderate to high and certainty of evidence was low to very low; only cerebrolysin had enough trials to show a (modest) cognition benefit
Cortexin® (10 μg/ml) demonstrated high or moderate binding to AMPA-receptors (80.1%), kainate receptors (73.5%), mGluR1 (49.0%), GABAA1 (44.0%) and mGluR5 (39.7%).
Kurkin DV, Bakulin DA, Morkovin EI, Kalatanova AV, Makarenko IE, Dorotenko AR, Kovalev NS, Dubrovina MA, Verkholyak DV, Abrosimova EE, Smirnov AV, Shmidt MV, Tyurenkov IN. · PLoS One (2021)
Best mechanistic study: rat acute (MCAO) and chronic (carotid stenosis) ischemia models plus in-vitro receptor binding and BBB-permeability assays
Radiolabeled cortexin crossed the blood-brain barrier (6-8% of whole-blood concentration) and bound AMPA/kainate/mGluR/GABA-A receptors in vitro
Cortexin reduced necrosis size in acute ischemia, supported the antioxidant system and limited neurodegeneration in chronic ischemia — comparable to cerebrolysin, better than actovegin
The use of cellex in comparison with cortexin is more effective in terms of the dynamics of regression of neurological and neurocognitive dysfunctions in patients with ERPIS.
Khabirov FA, Khaibullin TI, Granatov EV, Akhmetova GI, Akhmetzyanov NM. · Zh Nevrol Psikhiatr Im S S Korsakova (2020)
Randomized comparative human trial (40 patients) of Cellex vs cortexin (10 mg IM daily for 10 days) in early-recovery ischemic stroke
Cellex produced significantly greater improvement on NIHSS and MMSE than cortexin
A trend toward greater regression of depressive symptoms also favored Cellex
The most complete regression of neurological deficits and manifestations of cardiac autonomic neuropathy during the acute period of ischemic stroke was observed in the group of patients treated with cortexin.
Mashin VV, Belova LA, Aizatullin IF, Pavlova VA, Slasten EV, Abramova VV, Belov DV. · Zh Nevrol Psikhiatr Im S S Korsakova (2019)
Three-arm controlled (non-blinded) trial in 90 acute ischemic-stroke patients: cortexin 20 mg/day + early verticalization vs verticalization alone vs basic therapy
The cortexin arm showed the most complete regression of neurological deficits and cardiac autonomic neuropathy
Assessed with NIHSS, modified Rankin, Barthel, Rivermead, MMSE and MoCA
It was noted more rapid and complete regression of cognitive disorders in patients of the 1st and 2nd groups, in comparison with patients of the 3rd group.
Belova LA, Mashin VV, Abramova VV, Proshin AN, Ovsjannikova AN. · Zh Nevrol Psikhiatr Im S S Korsakova (2016)
Controlled (non-blinded) trial in 90 hemispheric ischemic-stroke patients comparing single vs double cortexin courses (20 mg/day) vs basic therapy
Cortexin groups showed faster and more complete regression of cognitive deficits than basic therapy alone
The double-course regimen gave the best cognitive outcome (MMSE, FAB, clock-drawing, MoCA)